SURF - Surface Oncology, Inc.
| Previous Close | 2.0000 |
| Open | 1.9700 |
| Bid | 2.2000 x 1000 |
| Ask | 4.6600 x 1000 |
| Day's Range | 1.9700 - 2.4200 |
| 52 Week Range | 1.1500 - 9.0800 |
| Volume | 190,371 |
| Avg. Volume | 87,603 |
| Market Cap | 62.457M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5660 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.25 |
- GlobeNewswire
Surface Oncology to Present at Evercore ISI 2nd Annual HealthCONx Conference
CAMBRIDGE, Mass., Nov. 26, 2019 -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
- GlobeNewswire
Surface Oncology Announces $25 Million Debt Financing from K2 HealthVentures
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced it has secured a debt financing facility for up to $25 million from K2 HealthVentures, a healthcare-focused specialty finance company. Surface received a first tranche of $7.5 million upon closing. “Securing this debt facility bolsters our financial position and increases our financial flexibility as we advance our next wave of programs into clinical development,” said Jeff Goater, chief executive officer of Surface Oncology.
- GlobeNewswire
Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to support the initiation of a phase 1/1b clinical study of SRF617 (targeting CD39). At an inaugural R&D day today, the Company will share progress across its portfolio including clinical development plans for SRF617 and SRF388 (IL-27), and preclinical data supporting its new development candidate, SRF813, which targets the recently identified checkpoint protein CD112R to promote natural killer (NK) and T cell activation. “We welcome this opportunity to dive into the compelling data underpinning our lead programs’ differentiated approaches to overcoming the immunosuppressive tumor microenvironment, as we work to break through and bring the benefits of immunotherapy to more patients suffering with cancer,” said Jeff Goater, chief executive officer of Surface Oncology.
- Zacks
Surface Oncology, Inc. (SURF) Reports Q3 Loss, Lags Revenue Estimates
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -5.17% and -86.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2019
CAMBRIDGE, Mass., Nov. 12, 2019 -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
- GlobeNewswire
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting
CAMBRIDGE, Mass., Nov. 07, 2019 -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
- ACCESSWIRE
Kaskela Law LLC Announces Investigation of Surface Oncology, Inc. on Behalf of Investors - SURF
PHILADELPHIA, PA / ACCESSWIRE / October 26, 2019 / Kaskela Law LLC announces that it is investigating Surface Oncology, Inc. (Nasdaq:SURF) on behalf of the Company's investors. In April 2018, Surface Oncology ...
- GlobeNewswire
Surface Oncology to Host Analyst and Investor Day on November 18, 2019 in New York City
Keynote speaker: E. John Wherry, Ph.D., director, Penn Institute for Immunology, University of Pennsylvania, and Co-Director of the Parker Institute for Cancer Immunotherapy at.
- Simply Wall St.
Here's Why Surface Oncology (NASDAQ:SURF) Must Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- ACCESSWIRE
IPO INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 18, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, ...
- PR Newswire
Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc.
NEW YORK , Sept. 17, 2019 /PRNewswire/ -- Curaleaf Holdings, Inc. (CURLF) Lifshitz & Miller announces investigation into possible securities laws violation in connection with the FDA's warning letter to ...
- GlobeNewswire
Surface Oncology to Present at the Baird 2019 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 03, 2019 -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.
- ACCESSWIRE
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 3, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, ...
- GlobeNewswire
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
Surface Oncology (SURF), today announced Ramy Ibrahim, M.D., will join the company’s board of directors. Dr. Ibrahim is a medical oncologist currently serving as chief medical officer and vice president of clinical development at the Parker Institute for Cancer Immunotherapy.
- GlobeNewswire
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, Inc. (“Surface” or “the Company”) (NASDAQ: SURF) for false and misleading SEC filings. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
- GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating Casa Systems, Greenlane Holdings, Surface Oncology, and Sunnova Energy on Behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 27, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Casa Systems, Inc. (NASDAQ: CASA), Greenlane Holdings, Inc. (NASDAQ: GNLN),.
- ACCESSWIRE
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 21, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, ...
- ACCESSWIRE
URGENT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 20, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, ...
- ACCESSWIRE
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 15, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, ...
- GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating Casa Systems, Greenlane Holdings, Surface Oncology, and Pintec Technology on Behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 14, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Casa Systems, Inc. (NASDAQ: CASA), Greenlane Holdings, Inc. (NASDAQ: GNLN),.
- ACCESSWIRE
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 12, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, ...
- ACCESSWIRE
URGENT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, ...
- ACCESSWIRE
IMPORTANT INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 7, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, ...
- GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating Greenlane Holdings, Surface Oncology, and Pintec Technology on Behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 07, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Greenlane Holdings, Inc. (NASDAQ: GNLN), Surface Oncology, Inc. (NASDAQ:.
